Time: 5pm amsterdam
Date: June 8, 2023
Starting from the concept and principles of Nucleic Acid Immunity, I will explain why TLR7 and TLR9 are unique among the nucleic acid immune sensing receptors for their ability to activate IFN-a secretion from plasmacytoid dendritic cells, and how their agonists can be used to activate innate immunity to optimize cancer immunotherapy.
What is your research about?
Developing a CpG-A DNA agonist for TLR9 in a virus-like particle for cancer immunotherapy